A Phase II Study of Glembatumumab Vedotin, an Anti-gpNMB Antibody -Drug Conjugate, in Patients with Advanced Melanoma
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Celldex Therapeutics, Inc.
Start Date
October 1, 2015
End Date
July 5, 2019
Administered By
Duke Cancer Institute
Awarded By
Celldex Therapeutics, Inc.
Start Date
October 1, 2015
End Date
July 5, 2019